title: Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
abstract: BACKGROUND
  The objective of this multicenter, prospective uncontrolled phase II trial was to determine efficacy, safety and tolerability of vatalanib, an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor receptors, in the second-line treatment of non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Patients with stage IIIB/IV NSCLC-proven tumor progression during or after one platinum-based chemotherapy regimen received a fixed dose of 1250 mg vatalanib either once-daily dosing (QD) or two divided daily dosing (TDD: 500 mg a.m. + 750 mg p.m.) until disease progression or unacceptable toxicity. Primary end point was the disease control rate (DCR) at 12 weeks.
  
  
  RESULTS
  Fifty-four and 58 patients were enrolled to the QD and TDD arms. DCR at 12 weeks was 35% in the QD and 37% in the TDD arm. The best overall response included one (2%) patient with confirmed partial response with QD and three (5%) with TDD. Median progression-free survival and overall survival were 2.1/7.3 months in the QD arm and 2.8/9.0 months with TDD arm. This therapy showed a moderate toxicity profile for the majority of patients.
  
  
  CONCLUSIONS
  In the chosen patient population, vatalanib QD and TDD dosing demonstrated potential benefits in tumor size reduction, DCR, and survival.
authors: Department of Medicine (Cancer Research), West German Tumor Center, University Hospital of University Duisburg-Essen, Essen, Germany. Electronic address: Thomas.gauler@uk-essen.de.
authors: T C
authors: TC
authors: Gauler
authors: Institut Gustave Roussy, Villejuif, France.
authors: B
authors: B
authors: Besse
authors: Institut Gustave Roussy, Villejuif, France.
authors: A
authors: A
authors: Mauguen
authors: Hopital La Pitié-Salpetriere, Paris.
authors: J B
authors: JB
authors: Meric
authors: Hopital Tenon, Paris, France.
authors: V
authors: V
authors: Gounant
authors: University Medical Center of the Johannes Gutenberg University Mainz, Mainz.
authors: B
authors: B
authors: Fischer
authors: University Hospital Goettingen, Goettingen.
authors: T R
authors: TR
authors: Overbeck
authors: Bayer Healthcare Pharmaceuticals, Berlin, Germany.
authors: H
authors: H
authors: Krissel
authors: Bayer Healthcare Pharmaceuticals, Berlin, Germany.
authors: D
authors: D
authors: Laurent
authors: Bayer Oy, Espoo, Finland.
authors: M
authors: M
authors: Tiainen
authors: Institut Gustave Roussy, Villejuif, France.
authors: F
authors: F
authors: Commo
authors: Institut Gustave Roussy, Villejuif, France.
authors: J C
authors: JC
authors: Soria
authors: Department of Medicine (Cancer Research), West German Tumor Center, University Hospital of University Duisburg-Essen, Essen, Germany.
authors: W E E
authors: WEE
authors: Eberhardt